Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Clinical trial NCT05418010 · RECRUITING
Trial details
- NCT number
- NCT05418010
- Sponsor
- Queen Mary University of London
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-01
- Primary completion
- 2027-10-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.